The University of British Columbia
UBC - A Place of Mind
The University of British Columbia
Peter A. Allard School of LawINTELLECTUAL PROPERTY LAW 422
  • Course Stream
  • Issues/Your Take
  • Syllabus Spring 2025
    • Syllabus Spring 2025
    • Syllabus Fall 2024
    • Syllabus Spring 2024
    • Syllabus Fall 2023
    • Syllabus Spring 2023
    • Syllabus Fall 2022
    • Syllabus Spring 2022
    • Syllabus Fall 2021
    • Syllabus Spring 2021
    • Syllabus Spring 2020
  • Course Video & Notes
  • Statutes
  • Socrates A.I.
  • About
    • Thanks
    • Allan Switzer
    • Community/Participate
    • Graham’s Bio
    • Jon’s Bio
» Peter A. Allard School of Law » Home » 2024 » October » 08 » Settlement of Patent Case With Potential to Limit Reach of Ozempic

Settlement of Patent Case With Potential to Limit Reach of Ozempic

By Miles Schaffrick on October 8, 2024

I find the use of intellectual properties to limit access to pharmaceutical drugs extremely interesting, particularly in face of international agreements such as the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).

Recently, pharmaceutical companies Mylan Pharmaceuticals and Novo Nordisk settled a patent dispute over Ozempic, the popular weight loss drug indicated for type 2 diabetes. The settlement follows a 2022 lawsuit by Novo Nordisk against Mylan Pharmaceuticals in response to an abbreviated New Drug Application for a generic version of Ozempic.

In its lawsuit, Novo alleged that Mylan’s application for a generic version of Ozempic violated dozens of patents. Unfortunately, the settlement details are undisclosed, so the status of generic Ozempic hangs in limbo.

Back in September, the CEO of Novo was called to answer questions by the US Senate Health, Education, Labor and Pension committee on the high costs of Ozempic. Specifically, the Nova CEO was questioned why Ozempic costs Americans $969 per month while Canadians pay $155 a month and Germans $59 per month. The spat with Mylan over a potential generic version of Ozempic follows a recent study that found Ozempic could be manufactured at significantly lower cost.

It will be interesting to see what happens in the coming years surrounding generic Ozempic and the patent protections of what are often life-saving drugs.

Article on the settlement of patent dispute between Mylan Pharmaceuticals and Novo Nordisk: https://www.biospace.com/policy/novo-viatris-settle-ozempic-patent-row

Article on CEO of Novo Nordisk’s US Senate hearing: https://www.cbsnews.com/news/ozempic-wegovy-price-novo-nordisk-senate-committee-hearing

Read More | No Comments

  • Previous
  • Next

Copyright & Social Media
Communications Law


Top Commented

  • Another look at digital ownership: California district judge entertains lawsuit against Apple re iTunes “Buy” button
  • How Trademarks Can Potentially Promote Sustainable Fashion
  • Lionel Ritchie sells homes?
  • A Copyright of a Copyright
  • Green branding in Canada… is this kind of branding merely descriptive or a proprietary tool?
  • Featured

  • Patent Law Regime in Canada V/S United States


  • Tweets by jonfestinger


    Creative Commons License
    Peter A. Allard School of Law, University of British Columbia
    1822 East Mall
    Vancouver, BC Canada V6T 1Z1
    Tel 604 822 3151
    Fax 604 822 8108
    Website allard.ubc.ca
    Back to top
    The University of British Columbia
    • Emergency Procedures |
    • Terms of Use |
    • Copyright |
    • Accessibility